BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35173274)

  • 21. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
    Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
    Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
    Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
    PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia.
    Cardoso BA; Duque M; Gírio A; Fragoso R; Oliveira ML; Allen JR; Martins LR; Correia NC; Silveira AB; Veloso A; Kimura S; Demoen L; Matthijssens F; Jeha S; Cheng C; Pui CH; Grosso AR; Neto JL; De Almeida SF; Van Vlieberghe P; Mullighan CG; Yunes JA; Langenau DM; Pflumio F; Barata JT
    Haematologica; 2024 Jun; 109(6):1713-1725. PubMed ID: 38058200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
    Palomero T; Ferrando A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
    Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
    J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
    Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
    PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-θ and reactive oxygen species.
    Giambra V; Jenkins CR; Wang H; Lam SH; Shevchuk OO; Nemirovsky O; Wai C; Gusscott S; Chiang MY; Aster JC; Humphries RK; Eaves C; Weng AP
    Nat Med; 2012 Nov; 18(11):1693-8. PubMed ID: 23086478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia.
    Lin S; Tian L; Shen H; Gu Y; Li JL; Chen Z; Sun X; You MJ; Wu L
    Oncogene; 2013 Oct; 32(40):4845-53. PubMed ID: 23108395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
    Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.
    King B; Trimarchi T; Reavie L; Xu L; Mullenders J; Ntziachristos P; Aranda-Orgilles B; Perez-Garcia A; Shi J; Vakoc C; Sandy P; Shen SS; Ferrando A; Aifantis I
    Cell; 2013 Jun; 153(7):1552-66. PubMed ID: 23791182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-ALL pathogenesis requires a NOTCH1-driven MYC enhancer.
    Cancer Discov; 2014 Nov; 4(11):OF17. PubMed ID: 25367958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.
    Weng AP; Millholland JM; Yashiro-Ohtani Y; Arcangeli ML; Lau A; Wai C; Del Bianco C; Rodriguez CG; Sai H; Tobias J; Li Y; Wolfe MS; Shachaf C; Felsher D; Blacklow SC; Pear WS; Aster JC
    Genes Dev; 2006 Aug; 20(15):2096-109. PubMed ID: 16847353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
    Palomero T; Ferrando A
    Clin Cancer Res; 2008 Sep; 14(17):5314-7. PubMed ID: 18765521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1.
    Gekas C; D'Altri T; Aligué R; González J; Espinosa L; Bigas A
    Leukemia; 2016 Oct; 30(10):2002-2010. PubMed ID: 27125305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.
    Yatim A; Benne C; Sobhian B; Laurent-Chabalier S; Deas O; Judde JG; Lelievre JD; Levy Y; Benkirane M
    Mol Cell; 2012 Nov; 48(3):445-58. PubMed ID: 23022380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
    Asnafi V; Buzyn A; Le Noir S; Baleydier F; Simon A; Beldjord K; Reman O; Witz F; Fagot T; Tavernier E; Turlure P; Leguay T; Huguet F; Vernant JP; Daniel F; Béné MC; Ifrah N; Thomas X; Dombret H; Macintyre E
    Blood; 2009 Apr; 113(17):3918-24. PubMed ID: 19109228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
    Ntziachristos P; Tsirigos A; Van Vlierberghe P; Nedjic J; Trimarchi T; Flaherty MS; Ferres-Marco D; da Ros V; Tang Z; Siegle J; Asp P; Hadler M; Rigo I; De Keersmaecker K; Patel J; Huynh T; Utro F; Poglio S; Samon JB; Paietta E; Racevskis J; Rowe JM; Rabadan R; Levine RL; Brown S; Pflumio F; Dominguez M; Ferrando A; Aifantis I
    Nat Med; 2012 Feb; 18(2):298-301. PubMed ID: 22237151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.